What is Wedbush’s Forecast for Chimerix FY2028 Earnings?

Chimerix, Inc. (NASDAQ:CMRX) – Analysts at Wedbush upped their FY2028 earnings estimates for Chimerix in a research report issued on Tuesday, February 18th. Wedbush analyst D. Nierengarten now anticipates that the biopharmaceutical company will post earnings of $0.58 per share for the year, up from their prior estimate of $0.47. Wedbush currently has a “Outperform” rating and a $7.00 target price on the stock. The consensus estimate for Chimerix’s current full-year earnings is ($0.99) per share.

Separately, HC Wainwright reissued a “buy” rating and set a $11.00 target price on shares of Chimerix in a research report on Tuesday.

Chimerix Price Performance

NASDAQ CMRX opened at $4.82 on Wednesday. The company’s fifty day simple moving average is $3.64 and its 200-day simple moving average is $1.88. Chimerix has a 52 week low of $0.75 and a 52 week high of $5.15.

Institutional Trading of Chimerix

A number of institutional investors and hedge funds have recently modified their holdings of the business. Deerfield Management Company L.P. Series C acquired a new stake in shares of Chimerix during the fourth quarter worth $13,124,000. Rosalind Advisors Inc. acquired a new stake in shares of Chimerix during the fourth quarter worth $10,614,000. Millennium Management LLC raised its holdings in shares of Chimerix by 6.8% during the fourth quarter. Millennium Management LLC now owns 2,557,530 shares of the biopharmaceutical company’s stock worth $8,900,000 after purchasing an additional 161,795 shares during the period. Marshall Wace LLP raised its holdings in shares of Chimerix by 1,318.5% during the fourth quarter. Marshall Wace LLP now owns 2,213,940 shares of the biopharmaceutical company’s stock worth $7,705,000 after purchasing an additional 2,057,864 shares during the period. Finally, Boxer Capital Management LLC acquired a new stake in shares of Chimerix during the fourth quarter worth $7,169,000. 45.42% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Chimerix

In other Chimerix news, CEO Michael T. Andriole sold 7,370 shares of the stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $4.52, for a total transaction of $33,312.40. Following the sale, the chief executive officer now directly owns 609,603 shares of the company’s stock, valued at approximately $2,755,405.56. This represents a 1.19 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold 20,760 shares of company stock valued at $91,175 over the last ninety days. Corporate insiders own 13.10% of the company’s stock.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.